Combination of bevacizumab plus irinotecan in recurrent malignant gliomas (MG): A retrospective study of efficacy and safety

被引：0
|
作者：
Gil Gil, M. J., Sr.
Martinez-Garcia, M.
Reynes, G.
Costas, E.
Fernandez-Chacon, C.
Pernas, S.
Benavides, M.
Herrero, A.
Perez-Martin, J.
Balana, C.
机构：
[1] Inst Catala Oncol, Barcelona, Spain
[2] Hosp Univ La Fe, Valencia, Spain
[3] MD Anderson Espana Int, Madrid, Spain
[4] Hosp Carlos Haya, Malaga, Spain
[5] Hosp Miguel Servet, Zaragoza, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13011
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Irinotecan and Bevacizumab in Children with Malignant Gliomas and Recurrent/Refractory Central Nervous System Tumors
    Cisneros, Gabriel Salinas
    Dager, Sarah
    Khatib, Ziad
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S52 - S53
  • [32] A phase II safety study of bevacizumab in patients with multiple recurrent or progressive malignant gliomas
    Raizer, Jeffrey
    Gallot, Lilia
    Levy, Robert
    Getch, Christopher
    Mellot, Ann
    Newman, Steven
    Tellez, Claudia
    Batjer, Hunt
    Marymont, Maryanne
    Chandler, James
    NEURO-ONCOLOGY, 2007, 9 (04) : 530 - 530
  • [33] A phase II safety study of bevacizumab in patients with multiple recurrent or progressive malignant gliomas
    Raizer, J. J.
    Gallot, L.
    Cohn, R.
    Chandler, J.
    Levy, R.
    Getch, C.
    Batjer, H.
    Marymont, M.
    Tellez, C.
    Mellot, A.
    Newman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas
    Seystahl, Katharina
    Wiestler, Benedikt
    Hundsberger, Thomas
    Happold, Caroline
    Wick, Wolfgang
    Weller, Michael
    Wick, Antje
    EUROPEAN NEUROLOGY, 2013, 69 (02) : 95 - 101
  • [35] BEVACIZUMAB ALONE OR IN COMBINATION WITH IRINOTECAN IN RECURRENT WHO GRADE II AND GRADE III GLIOMAS
    Seystahl, K.
    Wiestler, B.
    Hundsberger, T.
    Happold, C.
    Wick, W.
    Weller, M.
    Wick, A.
    NEURO-ONCOLOGY, 2012, 14 : 62 - 62
  • [36] Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours
    Poulsen, Hans Skovgaard
    Grunnet, Kirsten
    Sorensen, Morten
    Olsen, Preben
    Hasselbalch, Benedikte
    Nelausen, Knud
    Kosteljanetz, Michael
    Lassen, Ulrik
    ACTA ONCOLOGICA, 2009, 48 (01) : 52 - 58
  • [37] Bevacizumab and chemotherapy for recurrent malignant gliomas: Efficacy, toxicity, and recurrence patterns
    Norden, Andrew
    Young, Geoffrey S.
    Setayesh, Kian
    Muzikansky, Alona
    Klufas, Roman
    Ross, Gina L.
    Ciampa, Abigail S.
    Ebbeling, Laura G.
    Levy, Brenda
    Drappatz, Jan
    Kesari, Santosh
    Wen, Patrick
    NEUROLOGY, 2008, 70 (11) : A110 - A111
  • [38] Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study
    Gururangan, Sridharan
    Chi, Susan N.
    Poussaint, Tina Young
    Onar-Thomas, Arzu
    Gilbertson, Richard J.
    Vajapeyam, Sridhar
    Friedman, Henry S.
    Packer, Roger J.
    Rood, Brian N.
    Boyett, James M.
    Kun, Larry E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 3069 - 3075
  • [39] Bevacizumab plus irinotecan in recurrent glioblastoma - Reply
    Vredenburgh, James J.
    Desjardins, Annick
    Reardon, David A.
    Friedman, Henry S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 1013 - 1013
  • [40] Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
    Vredenburgh, James J.
    Desjardins, Annick
    Herndon, James E., II
    Marcello, Jennifer
    Reardon, David A.
    Quinn, Jennifer A.
    Rich, Jeremy N.
    Sathornsumetee, Sith
    Gururangan, Sridharan
    Sampson, John
    Wagner, Melissa
    Bailey, Leighann
    Bigner, Darell D.
    Friedman, Allan H.
    Friedman, Henry S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4722 - 4729
12345